Transcriptional analysis of an E2F Gene signature as a biomarker of activity of the cyclin-dependent kinase inhibitor PHA-793887 in tumor and skin biopsies from a phase I clinical study

Molecular Cancer Therapeutics

Volumn 9, Issue 5, 2010, Pages 1265-1273

  Locatelli, Giuseppe ^a   Bosotti, Roberta ^a   Ciomei, Marina ^a   Brasca, Maria G ^a   Calogero, Raffaele ^b   Mercurio, Ciro ^c   Fiorentini, Francesco ^d   Bertolotti, Matteo ^a   Scacheri, Emanuela ^a   Scaburri, Angela ^a   Galvani, Arturo ^a   Pesenti, Enrico ^a   De Baere, Thierry ^e   Soria, Jean Charles ^e   Lazar, Vladimir ^e   Isacchi, Antonella ^a  

^a NERVIANO MEDICAL SCIENCES   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c Genextra Group   (Italy)

^d Attrition Reducing Technologies   (Italy)

^e INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR; PHA 793887; TRANSCRIPTION FACTOR E2F; UNCLASSIFIED DRUG;

ANGIOMYOLIPOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE DUCT CARCINOMA; BREAST CARCINOMA; CANCER PATIENT; CELL CYCLE REGULATION; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG DOSE ESCALATION; DRUG MECHANISM; ENZYME INHIBITION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; LEIOMYOSARCOMA; MICROARRAY ANALYSIS; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; NUCLEOTIDE SEQUENCE; PAROTID GLAND CARCINOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SARCOMA; SKIN BIOPSY; SOLID TUMOR; TRANSCRIPTION REGULATION; TUMOR BIOPSY; TUMOR XENOGRAFT; UTERUS SARCOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOMARKERS, PHARMACOLOGICAL; BIOPSY; CELL LINE, TUMOR; CLINICAL TRIALS, PHASE I AS TOPIC; CYCLIN-DEPENDENT KINASES; E2F TRANSCRIPTION FACTORS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, NUDE; NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PYRAZOLES; PYRROLES; SKIN; TRANSCRIPTIONAL ACTIVATION; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77952126279     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-1163     Document Type: Article

References (44)

1. Chung CH, Bernard PS, Perou CM. Molecular portraits and the family tree of cancer. Nat Genet 2002;32 Suppl:533-540
2. van't Veer LJ, Bernards R. Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature 2008;452: 564-570
3. Phillips RL, Sachs AB. Skin biopsies for the measurement of clinical pharmacodynamic biomarkers. Curr Opin Biotechnol 2005;16: 687-690
4. Williams R, Baker AF, Ihle NT, Winkler AR, Kirkpatrick L, Powis G. The skin and hair as surrogate tissues for measuring the target effect of inhibitors of phosphoinositide-3-kinase signaling. Cancer Chemother Pharmacol 2006;55:444-450
5. Colburn WA. Biomarkers in drug discovery and development: from target identification through drug marketing. J Clin Pharmacol 2003;43:329-341
6. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995;81:323-330
7. Lundberg AS, Weinberg RA. Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol Cell Biol 1998;18:753-761
8. 1. Cell 1999;98:859-869
9. Nevins JR. The Rb/E2F pathway and cancer. Hum Mol Genet 2001; 10:699-703.
10. Scambia G, Lovergine S, Masciullo V. RB family members as predictive and prognostic factors in human cancer. Oncogene 2006;25:5302-5308
11. Muller H, Bracken AP, Vernell R, et al. E2Fs regulate the expression of genes involved in differentiation, development, proliferation, and apoptosis. Genes Dev 2001;15:267-285
12. Ishida S, Huang E, Zuzan H, et al. Role for E2F in control of both DNA replication and mitotic functions as revealed from DNA microarray analysis. Mol Cell Biol 2001;21:4684-4699
13. Ren B, Cam H, Takahashi Y, et al. E2F integrates cell cycle progression with DNA repair, replication, and G(2)/M checkpoints. Genes Dev 2002;16:245-256
14. Polager S, Kalma Y, Berkovich E, Ginsberg D. E2Fs upregulated expression of genes involved in DNA replication, DNA repair and mitosis. Oncogene 2002;21:437-446
15. Wells J, Graveel CR, Bartley SM, et al. The identification of E2F1-specific target genes. Proc Natl Acad Sci U S A 2002;99:3890-3895
16. Takahashi Y, Rayman JB, Dynlacht BD. Analysis of promoter binding by the E2F and pRB families in vivo: distinct E2F proteins mediate activation and repression. Genes Dev 2000;14:804-816
17. Brasca MG, Albanese C, Alzani R, et al. Optimisation of 6,6-dimethyl pyrrolo[3,4-c]pyrazoles: identification of PHA-793887, a potent CDK inhibitor suitable for intravenous dosing. Bioorg Med Chem 2010;18: 1844-1853.
18. http://www.tm4.org.
19. http://www.bioconductor.org.
20. Wu Z, Irizarry RA, Gentleman R, Martinez Murillo F, Spencer F. A model based background adjustment for oligonucleotide expression arrays. John Hopkins University, Department of Biostatistics Working papers; 2004, Paper1.
21. http://www.ncbi.nlm.nih.gov/geo.
22. Sanges R, Cordero F, Calogero RA. oneChannelGUI: a graphical interface to Bioconductor tools, designed for life scientists who are not familiar with R language. Bioinformatics 2007;23:3406-3408
23. Whittaker SR, Te Poele RH, Chan F, et al. The cyclin-dependent kinase inhibitor seliciclib (R-roscovitine; CYC202) decreases the expression of mitotic control genes and prevents entry into mitosis. Cell Cycle 2007;6:3114-3131
24. Berkofsky-Fessler W, Nguyen TQ, Delmar P, et al. Preclinical biomarkers for a cyclin-dependent kinase inhibitor translate to candidate pharmacodynamic biomarkers in phase I patients. Mol Cancer Ther 2009;8:2517-2525
25. ClinicalTrials.gov record number NCT00996255.
26. Senderowicz AM. Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials. Invest New Drugs 1999;17:313-320
27. Meijer L, Bettayeb K, Galons H. (R)-roscovitine (CYC202, seliciclib). In: Smith PJ, Yue EW, editors. Inhibitors of cyclin-dependent kinases as anti-tumor agents. Boca Raton (FL): CRC Press; 2006, p. 87-225.
28. Misra RN, Xiao H, Kim KS, et al. N-(cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5[[[5-(1,1-dimethylethyl)-2- oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent. J Med Chem 2004;47:1719-1728
29. Toogood PL, Harvey PJ, Repine JT, et al. Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6. J Med Chem 2005; 48:2388-2406
30. Chu XJ, DePinto W, Bartkovitz D, et al. Discovery of [4-amino-2-(1- methanesulfonylpiperidin-4-ylamino)pyrimidin-5-yl](2,3-difluoro-6-methoxyphenyl) methanone (R547), a potent and selective cyclin-dependent kinase inhibitor with significant in vivo antitumor activity. J Med Chem 2006;49:6549-6560
31. Parry D, Guzi T, Seghezzi W, et al. In vitro and in vivo characterization of SCH-727965, a novel potent cyclin dependent kinase inhibitor. AACR Conference, Los Angeles (CA). 2007, Poster 4371.
32. Wyatt PG, Woodhead AJ, Berdini V, et al. Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design. J Med Chem 2008;51:4986-4999
33. Jones CD, Andrews DM, Barker AJ, et al. The discovery of AZD5597, a potent imidazole pyrimidine amide CDK inhibitor suitable for intravenous dosing. Bioorg Med Chem Lett 2008;18:6369-6373
34. Brasca MG, Amboldi N, Ballinari D, et al. Identification of N,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4, 5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor. J Med Chem 2009;52:5152-5163
35. Tan AR, Yang X, Berman A, et al. Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer. Clin Cancer Res 2004;10: 5038-5047
36. Haddad RI, Weinstein LJ, Wieczorek TJ, et al. A phase II clinical and pharmacodynamic study of E7070 in patients with metastatic, recurrent, or refractory squamous cell carcinoma of the head and neck: modulation of retinoblastoma protein phosphorylation by a novel chloroindolyl sulfonamide cell cycle inhibitor. Clin Cancer Res 2004;10:4680-4687
37. Hsieh WS, Soo R, Peh BK, et al. Pharmacodynamic effects of seliciclib, an orally administered cell cycle modulator in undifferentiated nasopharyngeal cancer. Clin Cancer Res 2009;15:1435-1442
38. Bild AH, Yao G, Chang JT, et al. Oncogenic pathway signature in human cancers as a guide to targeted therapies. Nature 2006;439: 353-357
39. Whitfield ML, George LK, Grant GD, Perou CM. Common markers of proliferation. Nat Rev Cancer 2006;6:99-106.
40. Alzani R, Albanese C, Locatelli G, et al. Biological characterization of the dual CDK2/TRKA inhibitor PHA-848125 [abstract 294]. Eur J Cancer Suppl 2008;6:94.
41. Boss DS, Schwartz GK, Middleton MR, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumors. Ann Oncol 2010;21:884-894
42. Squires MS, Lock V, Adam J, et al. Identification of a predicted biologically effective dose of AT7519, a cyclin-dependent kinase inhibitor, in a phase I study. AACR 100th Annual Meeting 2009, Denver (CO). 2009, Poster 3588.
43. Camidge DR, Pemberton M, Growcott J, et al. A phase I pharmacodynamic study of the effects of the cyclin-dependent kinase-inhibitor AZD5438 on cell cycle markers within the buccal mucosa, plucked scalp hairs and peripheral blood mononucleocytes of healthy male volunteers. Cancer Chemother Pharmacol 2007;60: 479-488
44. Chen HZ, Tsai SY, Leone G. Emerging roles of E2Fs in cancer: an exit from cell cycle control. Nat Rev Cancer 2009;9:785-797